JAB-8263 for Solid Tumors

SCRI HeatlthONE, Denver, CO
Solid TumorsJAB-8263 - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new cancer drug to see what dose is safe and how it affects people with advanced solid tumors.

Eligible Conditions
  • Solid Tumors, Adult

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 1

Similar Trials

Study Objectives

2 Primary · 7 Secondary · Reporting Duration: Approximately 2.5 years

Approximately 2.5 years
Area under the curve
Duration of response ( DOR )
Find Recommended Phase 2 Dose (RP2D) of JAB-8263
Number of participants with adverse events
Number of participants with dose limiting toxicities
Objective response rate ( ORR )

Trial Safety

Phase-Based Safety

1 of 3

Similar Trials

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

1 of 1

Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: JAB-8263 · No Placebo Group · Phase 1

Experimental Group · 1 Intervention: JAB-8263 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: approximately 2.5 years

Who is running the clinical trial?

Jacobio Pharmaceuticals Co., Ltd.Lead Sponsor
15 Previous Clinical Trials
1,399 Total Patients Enrolled
Jacobio PharmaceuticalsStudy DirectorJacobio Pharmaceuticals
7 Previous Clinical Trials
613 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 0 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

How does this experiment strive to improve patient outcomes?

"This trial, which is slated to last for two-and-a-half years, seeks to identify the appropriate dosage of JAB-8263. Secondary aims include assessing duration of response (DOR), peak plasma concentration (Cmax) and adverse events associated with treatment." - Anonymous Online Contributor

Unverified Answer

What is the target enrollment size of this experiment?

"Jacobio Pharmaceuticals Co., Ltd. is the sponsor responsible for running this trial, which requires 30 participants who meet its inclusion criteria. The two primary sites are Tennessee Oncology Nashville in Nashville, Tennessee and SCRI HealthONE in Denver, Colorado." - Anonymous Online Contributor

Unverified Answer

Is the recruitment period open for this experiment?

"On clinicaltrials.gov, the data confirms that enrollment is still open for this study which was first launched on November 23rd 2020 and recently revised on March 11th 2022." - Anonymous Online Contributor

Unverified Answer

Has the regulatory body authorized JAB-8263 for public use?

"Based on the data currently available, JAB-8263 has been provisionally assigned a safety rating of 1 due to its current stage in clinical trials. At this point, there is minimal evidence for both efficacy and safety." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.